

AD _____

Award Number: DAMD17-99-1-9157

TITLE: Structural Studies of a New Nuclear Target for EGF
Receptor Tyrosine Kinases

PRINCIPAL INVESTIGATOR: Guillermo A. Calero, M.D., Ph.D.
Richard A. Cerione, Ph.D.
Jon Clardy, Ph.D.

CONTRACTING ORGANIZATION: Cornell University
Ithaca, New York 14853-2801

REPORT DATE: August 2001

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20020311 132

REPORT DOCUMENTATION PAGEForm Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE August 2001	3. REPORT TYPE AND DATES COVERED Annual Summary (15 Jul 00 - 14 Jul 01)	
4. TITLE AND SUBTITLE Structural Studies of a New Nuclear Target for EGF Receptor Tyrosine Kinases			5. FUNDING NUMBERS DAMD17-99-1-9157	
6. AUTHOR(S) Guillermo A. Calero, M.D., Ph.D. Richard A. Cerione, Ph.D. Jon Clardy, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Cornell University Ithaca, New York 14853-2801 E-Mail: gac9@cornell.edu			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES Report contains color				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited				12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words) This project involves structural studies of a nuclear target for the EGF receptor, and the related Neu/ErbB2 tyrosine kinase, named the CBC for RNA-capped binding protein complex. The CBC consists of two subunits, CBP20 (Mr 18 kDa) and CBP80 (Mr 90 Kda), and undergoes a growth factor (EGF, heregulin)-dependent binding of RNAs transcribed by the RNA polymerase II at a 5' cap structure that consists of a guanosine residue methylated at the N7 position. This represents a first key step in the cap-dependent splicing of precursor messenger RNA (mRNA) and in the nucleocytoplasmic transport of U snRNAs which are necessary for the formation of the spliceosome complexes. While, EGF stimulates CBC activity, it is most strongly stimulated by heregulin, an activator of the Neu/ErbB2 tyrosine kinase, and appears to be constitutive in breast cancer where Neu/ErbB2 expression is high. Thus, we believe that the CBC represents an exciting nuclear target for receptor tyrosine kinases, linking growth factor-dependent gene expression to RNA processing. We have solved the atomic structure of the CBC in complex with m7GpppG at 2.2 Å. The atomic structure of this triple complex represents the second eukaryotic cap binding structure solved to date and reveals interesting aspects of capped RNA binding and regulation.				
14. SUBJECT TERMS Breast Cancer				15. NUMBER OF PAGES 17
				16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

TABLE OF CONTENTS

Cover.....	1
SF 298.....	2
Table of Contents.....	3
Introduction.....	4
Body.....	5
Key Research Accomplishments.....	7
Reportable Outcomes.....	7
Conclusions.....	7
Appendices.....	9
References.....	15

INTRODUCTION

Normal and malignant human mammary epithelial cells are able to synthesize and to respond to various different, locally acting growth factors through specific receptors. Among these are the type 1 family of growth factor receptors, which consist of the epidermal growth factor receptor (EGF-R), ErbB2/Neu, ErbB3, and ErbB4 (1-6). They are required for normal mammary development and lactation and are aberrantly expressed in approximately 40% of breast carcinomas. Indeed, in human breast cancer cases the prognosis of a patient is inversely correlated with the over expression and/or amplification of this receptor family. The physiological regulatory ligand for ErbB2/Neu has been shown to be heregulin (7-9). Interaction of heregulin with the ErbB3 induces a heterodimerization between ErbB2 and ErbB3, which results in the transphosphorylation and activation of the ErbB2 receptor. Phosphorylation of this receptor initiates signaling cascades, which in turn can impact upon cell function, growth and division.

One way to regulate protein expression in the cell is achieved by controlling mRNA concentration. Cytoplasmic mRNA levels represent a balance between transcription, splicing and nuclear export on the one hand and mRNA degradation on the other. The balance between these two processes represents a major control point in gene expression. Recent studies have shown that post-transcriptional mechanisms regulate protein expression in certain cell lines. For example, down-regulation of the proto-oncogene c-myc mRNA during differentiation of C2C12 myoblasts to myotubes is mediated by a cytoplasmic mRNA turnover event rather than a nuclear processing event (10). More importantly, Balmer *et al* (11), have shown that the EGF-induced up-regulation of EGF-R mRNA in two human breast cancer cell lines that over-express EGF-R (MDA-MB-468 and BT-20) is accompanied by stabilization (>2-fold) of EGF-R mRNA. They showed that the EGF-R mRNA contains a novel complex AU-rich 260-nt cis-acting destabilizing element in the 3'-UTR that is bound by specific and EGF-regulated trans-acting factors.

Wilson *et al.* (12-13) have identified a novel nuclear target for heregulin signaling which responds to the growth factor treatment of cells with an increase ability to be labeled with GTP. They identified this target as the 20-kDa subunit of the nuclear cap binding complex (CBC) and demonstrated that the CBC is stimulated to bind to capped RNAs in response to heregulin. Based on these observations Wilson *et al* suggested that heregulin could impact upon cell growth by modulating gene expression at the level of RNA processing via the CBC. They further suggested that in a situation where the heregulin signal is constitutive, the active CBC could affect gene expression by amplifying the rate of RNA processing, and thus contribute to unregulated cell growth and division.

The CBC is comprised of a stable heterodimer between an 18-kDa subunit and a 90-kDa subunit (CBP20 and CBP80 respectively). Biochemical and genetic experiments have shown important roles for CBC in mRNA physiology including splicing (14-17), nuclear export (18-19), 3' end processing (20), translation initiation (21), nonsense mediated decay (NMD) (22) and mRNA degradation (23). Due to its active role in mRNA stability the CBC could play a role in protein expression. Regulation of CBC by growth factor signaling may represent in turn a mechanism to change cytosolic or nuclear protein levels.

We have solved the structure of the CBC at 2.2 Å resolution by molecular replacement (using as a model a partially proteolyzed CBC) and the phases from a Kr MAD dataset. Mazza *et al* (24) had previously published the structure of CBP80 and a proteolyzed fragment of CBP20 (residues 38-116). Due to proteolysis their structure could not answer several important questions such as how the cap binds to CBP20 and how CBP80 increases the affinity of CBP20 for the cap structure. The atomic structure reported here comprises CBP80, 95% of CBP20 (residues 7-153) and the cap structure analog m⁷GpppG.

BODY

1. Experimental Procedures

Purification and crystallization protocols for CBC were outlined in the previous report.

Solving the phase problem

Table 1 summarizes crystallographic and phasing data

Molecular Replacement

Model: CBP80 from Mazza et al. (24) and a fragment of CBP20

Correlation Coefficient: 24.7

Rfactor (%) 42

Refinement

Resolution (Å) 50-2.2

No of reflections (test set) 51677 (2571)

R_{crys}/R_{free} (%) 21.7/25.7

Number of atoms 7240

Water Molecules 391

Average B Factor (Å²) 40.2

Rms. bonds (Å) 0.007

Rms. angles (°) 1.6

Percent of residues in most favored regions 90.0%

Percent of residues in additionally allowed regions 9.4 %

2. Results

The CBC

Figure 1 illustrates the triple complex formed by CBP20, CBP80 and the cap analog m⁷GpppG. The atomic structure of CBP80 presented here is identical to the structure solved by Mazza et al. (24). CBP80 is all α helical and consists of three domains connected by two long linkers. Domains 1 (D1) and 3 (D3) are packed against domain 2 (D2) that constitutes the core of the protein. The N-terminal domain (D1) is structurally similar to the middle domain of eIF4G which plays a regulatory role in RNA translation and protein synthesis. Interestingly linker 1 connecting D1 and D2 contains a surface exposed proline rich sequence 268-PPFTPPPH-277 (P, conserved residue). Further biochemical experiments are needed to test possible interactions of this proline rich region with SH3 domains. The detailed structure of CBP80 was previously reported by Mazza et al. (24) and will not be the subject of this report.

Overall Fold of CBP20

The overall fold of CBP20 (Figure 2) is that of a classical ribonucleotide binding domain (RNP) and consists of four anti-parallel β -sheets packed against two α -helices. β 3 (residues 81-88) and β 1 (residues 41-46) form the RNP1 and RNP2 motifs respectively. Other important regions include the N-terminal region that interacts with CBP80, a loop (loop 3) between β 2 and β 3 and a C-terminal α -helix (α C) that participate in RNA binding. Modifications to the classical RNP fold include a long N-terminus and two insertions consisting of two sets of small anti-parallel β strands, the first between β 4 and α C and the second at the C-terminus.

Cap Binding to CBP20

The methylated guanidine ring of the cap analog m⁷GpppG binds inside a cavity in CBP20 (Figure 3). Recognition and binding of the cap structure requires the following: 1) Enhanced stacking interactions between the electron deficient m⁷ guanine ring and two electron rich aromatic residues (Y20 and Y43) (Figure 4). 2) A “planar” network of electrostatic interactions (hydrogen bonds and salt bridges) between the guanosine base and a semicircular loop (residues 112-133)(Figure 5). Mutagenesis studies in this region are needed to establish the contribution of each residue to cap recognition and binding.

The mechanisms for the stabilization of the non-methylated guanosine base of m⁷GpppG is similar to other reported RNP proteins and is achieved through hydrophobic interactions with V134, hydrogen bonding with main chain atoms (amide nitrogen of R127 and carbonyl oxygen of R129) and Y138.

Role of CBP80 in cap binding stabilization

Izaurrealde et al. (15) had shown previously that binding of the cap analog to CBC is inherently more stable than binding of the cap to CBP20 alone. This question was still outstanding after the publication of the structure of CBC by Mazza et al. (24). The N-terminus of CBP20 (residues 6-14) makes extensive hydrophobic and ionic interactions with residues from four α -helices (residues 31-39, 67-71, 323-335) in CBP80 (Figure 6). By stabilizing the N-terminus of CBP20 and the residues close to Tyr20 (stacking interactions with the m⁷-guanine ring) CBP80 increases the affinity of CBP20 for the cap structure.

Phosphorylation of Threonine 79

We have observed electron density for a possible phosphorylation site at Thr79 (loop 3). Comparison of this region between our structure and the structure of Mazza et al. (24) reveals a small change involving Tyr49 and Phe50 (figure 7) that could lead to stabilization of the C-terminus of CBP20 (which participates in RNA binding). At the moment this is just a speculation. Further experiments are needed to corroborate this finding and to establish the possible role of phosphorylation (if any) in RNA binding to CBP20.

Possible Loop3 movements upon cap RNA binding

Further comparisons between the bound structure reported here with the unbound structure reported by Mazza et al. (24) show potential rearrangements in loop 3. Upon RNA binding, Gly72 could function as a pivot point for loop 3 movements, since in the unbound structure Leu73 localizes to the cap-binding site (Figure 8). Most loop 3 regions (from sequences whose secondary structure and topology are known) vary in sequence and number of residues and can assume a wide range of conformations that could be important to RNA binding. We have recently obtained crystals of CBC without the cap analog. Solving this structure should provide important insights into the specific structural changes associated with cap binding.

A possible RNA binding region in CBP20

In RNP proteins, loops 1 and 3 and the C-terminal α C have been shown to participate in mRNA binding (25-26) A positively charged groove (Figure 9, blue arrows) is present on the surface of CBP20 just inferior to the non-methylated guanosine residue. This groove is formed from residues in loop 1 (floor), loop 3 and the C-terminal domain (lateral wall) in CBP20 and residues from CBP80 (opposing lateral wall and pocket). We have found a tubular electron density inside this pocket in CBP80 and we modeled it with a molecule of polyethylene glycol 400 (PEG400).

Is CBC a decapping enzyme?

Residues close to the ribose and the phosphates (Gln27, Gln133, and Arg127) in the cap-binding cavity present an architecture that could resemble the Ras/Ras-Gap complex (including Gln61 from Ras and Arg789 from RasGap). This finding raises the possibility that under certain circumstances (e.g. binding to another partner),

CBP20 could have decapping activity by hydrolyzing the gamma phosphate of m7Gppp. Interestingly, the yeast decapping enzyme, Dcp1p (25-kDa) shares 15.2% identity with CBP20 and has among its conserved residues, Tyr68 (Tyr43 in CBP20) which participates in cap binding (see above).

KEY RESEARCH ACCOMPLISHMENTS

- Expression of CBC in SF9 cells.
- Purification and crystallization of CBC.
- Solution of the atomic structure of CBC in complex with m7GpppG at 2.2 Å resolution.
- Refinement of the CBC structure with a final $R_{\text{free}}/R_{\text{factor}}$ of 25.7/21.7 and good geometry.
- Crystallization of the unbound complex

REPORTABLE OUTCOMES

- Manuscript in preparation:

ATOMIC STRUCTURE OF THE NUCLEAR CAP BINDING PROTEIN (CBP20) IN COMPLEX WITH CAP BINDING PROTEIN 80 (CBP80) AND THE CAP ANALOG m7GpppG.

G.A. Calero, K.F. Wilson, J.L. Rios, T.K. Ly, R.A. Cerione and J.C. Clardy.

CONCLUSIONS

We have solved the structure of the triple complex between CBP20, CBP80 and the cap analog m7GpppG at 2.2 Å resolution. The atomic structure of this triple complex represents the second eukaryotic cap binding structure solved to date, the first being eukaryotic initiation factor 4E (eIF4E), and includes key structural aspects that were not found in the partial structure for the CBC published by Mazza et al (24).

The fold of CBP20 conforms to a classical RNP fold and differs significantly from the other two cap binding proteins, eIF4E (8 stranded antiparallel β sheets packed against 3 long helices)(27) and the vaccinia virus cap binding protein VP39 (7 stranded β sheets surrounded by 5 parallel helices) (28-29).

Binding of the capped RNA to CBP20 is slightly different from cap binding by eIF4E and VP39. Table 2 illustrates some of these differences (29). The low B-factors observed (35-40 Å²) and the excellent electron density for the methylated guanosine base could indicate a tight interaction with CBP20.

An important aspect of the structure of the CBC is the possible stabilization of cap binding by CBP80. This is a novel finding for cap binding proteins and could represent an important regulatory mechanism. For example, we have seen that binding of importin- α to the N-terminal nuclear localization signal (NLS) of CBP80 increases cap affinity (see previous report). The structure of the CBC shows that residues in the N-terminus of CBP80 participate in cap stabilization, therefore interactions of importin- α with CBP80 could lead to increased cap-binding affinity. On the other hand, disruption of the CBC complex could lead to the release of capped RNA.

Two more aspects of the structure deserve comment. First, the strong electron density associated with T79 raises the possibility that this residue could be phosphorylated. Second, the supposition that CBP20 could be a decapping enzyme based on the structural similarities between the GTP binding site within the Ras/Ras-Gap and the cap-binding site within CBP20. At the moment, these are just speculations raised by structural findings and represent a clear example of how structure can drive biochemistry. Experiments are being

conducted (decapping assays) to investigate the role of the CBC in decapping using the yeast-decapping enzyme Dcp1p as a control.

The structure of CBP20 in complex with CBP80 and m7GpppG gives us new clues regarding how CBP20 a RNP protein, interacts with capped RNA and how CBP80 regulates this interaction. We know that CBP80 is needed for nuclear export of the CBC but the fact that CBP80 is significantly larger than CBP20 raises the possibility that CBP80 could also function as a scaffold for other proteins that could interact with CBP20 or the bound capped mRNA. The interaction of CBP20-CBP80 is reminiscent of the interaction between eIF4E and eIF4G (domain similarity with CBP80). In this case eIF4G works as a binding platform for other proteins such as eIF4E, eIF4A (a helicase) and the poly-A binding protein (30-32) among others.

New biochemical and structural studies are needed to fully understand the role of CBC in mRNA stability and how this can be influenced by signaling events via EGF-R or Neu/Erb2. During the last six months of my fellowship, I will concentrate on trying to obtain the structure of the unbound CBP20-CBP80 and to improve the crystals for the CBC-importin- α complex.




Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6

- m7GpppG
+ m7GpppG




Figure 7

- m7GpppG
+ m7GpppG




Figure 8




Figure 9

	<i>Native</i>	<i>Osmium</i>	<i>Kr λ_1 (edge)</i>		<i>Kr λ_2 (peak)</i>		<i>Kr λ_3 (remote)</i>	
			<i>1 site</i>		<i>1 site</i>		<i>1 site</i>	
Resolution (Å)	40-2.35	40-2.15	40-2.65		40-2.65		40-2.65	
Wavelength (Å)	0.9347	1.00	0.8651		0.8655		0.850	
Rmerge (%)	6.0	5.8	7.5		7.6		7.7	
I/σI	3.4	3.4	3.1		3.1		3.1	
Reflections	54292	70263	34246		34259		34160	
Redundancy	5.6		12.8		12.7		12.4	
Completeness	99%	99%	95%		95%		95%	
Rcullis (%)		0.87	Iso	Ano	Iso	Ano	Iso	Ano
			NA	0.92	0.5	0.92	0.51	0.91
Phasing Power		Iso	Iso	Ano	Iso	Ano	Iso	Ano
		1.1	NA	0.98	1.24	0.99	1.39	1.04

Table 1: Data collection statistics

	<i>Cavity Size</i>	<i>Second. Structure</i>	<i>Pi-Pi stacking residues</i>	<i>Hydrogen bonds</i>	<i>m7 Van der Waals contacts</i>	<i>PO4 Contacts</i>	<i>Ribose contacts</i>
CBC	+++	β strand, loop	Y20 Y43	8	none	Q133, R127	2 R123 1 R123
IF4E	++	Loop Loop	W 56 W102	3	W166	R157, L162	VdW W56
VP39	+	Helix Loop	Y22 F180	5	Y204	R177	None

Table 2

REFERENCES

1. Kraus, M.H., Issing, W., Miki, T., Popescu, N.C., and Aronson, S.A.. (1989). Isolation and characterization of ErbB3, a third member of the ErbB/epidermal growth factor receptor family: Evidence for overexpression in a subset of human mammary tumors". *Proc. Natl. Acad. Sci. USA*, **86**:9193-9197.
2. Slamon, D.J., Wong, S.G., Levin, W.J., Ullrich, A. and McGuire, W.L.. (1987). " Human breast cancer: Correlation of relapse and survival with amplification of the HER2/neu oncogene". *Science*, **235**:177-182.
3. Slamon, D.J., Godolphin, W.L., Jones, A., Holt, J.A., Wong, S.G., Keith, D.E., Levin, W.J., Stuart, S.G., Udove, J., Ullrich, A., and Press, M.F..(1989). " Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer". *Science*, **244**:707-712.
4. Van de Vijver, M., Van de Berselaar R., Devillee, P., Cornelisse, C., Peterse, J., and Nusse, R.. (1987). " Amplification of the neu (e-erbB-2) oncogene in human mammary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene". *Mol. Cell. Biol.*, **7**:2013-2023.
5. Tsuda, H., Hirashi, S., and Shimosato, Y..(1989). " Correlation between long-term survival in breast cancer patients and an amplification of two putative oncogene coamplification units: HST-1/int-2 and c-erbB2/ear-1". *Cancer Res.*, **29**:3104-3108.
6. Zhou, D., Battifora, H., Yokota, J., Yamamoto, T., and Cline, M.J.. (1987). "Association of multiple copies of the c-erbB2 oncogene with the spread of cancer". *Cancer Res.*, **47**:6123-6125.
7. Plowman, G.D., Culouscou, J.M., Whitney, G.S., Green, J.M., Carlton, G. W., Foy, L., Neubauer, M.G., and Shoyab, M.. (1993). "Ligand-specific activation of HER4/p180erbB4, a fourth member of the epidermal growth factor receptor family". *Proc. Natl. Acad. Sci. USA*, **90**:1746-1750.
8. Carraway, K.L., Sliwkowski, M.X., Akita, R., Platko, J.V., Guy, P.M., Nuijens, A., Diamonti, A.J., Vandlen, R.L., Cantley, L.C., and Cerione, R.A..(1994). "The erbB3 gene product is a receptor for heregulin.". *J Biol. Chem.*, **269**:14303-14306.
9. Sliwkowski, M.X., Schaefer, G., Akita, R.W., Lofgren, J.A., Fitzpatrick, V.D., Nuijens, A., Fendley, B.M., Cerione, R.A., Vandlen, R.L., and Carraway, K.L..(1994). "Coexpression of erbB2 and erbB3 proteins is required for a high affinity, signaling receptor heregulin". *J. Biol. Chem.*, **269**:14661-14665.
10. Yielding, N.M., Lee, W.M. *Coding elements in exon 2 and 3 target c-myc mRNA downregulation during myogenic differentiation.* (1997). *Mol Cell. Biol.* **17**:2698-2707.
11. Balmer L.A. Beveridge D.J., Thomson A.M. et al. Identification of a novel AU-Rich element in the 3' untranslated region of epidermal growth factor receptor mRNA that is the target for regulated RNA-binding proteins. (2001). *Mol Cell Biol.* 2001 Mar; **21**(6):2070-84.
12. Wilson, K.F., Fortes, P., Singh, U.S., Ohno, M., Mattaj, I.W., and Cerione, R.A..(1999). "The nuclear cap binding complex is a novel target of growth factor receptor-coupled signal transduction", *J. Biol. Chem.*, **274**:4166-4173.
13. Wilson, K.F., Wu W.J. and Cerione R. "CDC42 Stimulates RNA splicing via the S6 kinase and a Novel S6 kinase target, the nuclear cap binding complex. (2000)". *J. Biol. Chem.*, **275**:37307-37310.

14. Ohno, M., Sakamoto, H., and Simura, Y..(1987). "Preferential excision of the 5' proximal intron from mRNA precursors with two introns as mediated by the cap structure". *Proc. Natl. Acad. Scie. USA*, **84**:5187-5191.
15. Izaurralde, E., Lewis, J., McGuigan, C., Jankowska, M., Darzynkiewicz, E., and Mattaj, I.W.. (1994). "A nuclear cap binding protein complex involved in pre-mRNA splicing". *Cell*, **78**:657-668.
16. Lewis, J.D., Izaurralde, E., Jarmolowski, A., McGuigan, C., and Mattaj, I.W..(1996). "A nuclear cap binding complex facilitates association of U1snRNP with the cap proximal 5'splice site". *Genes &Dev.*, **10**:1683-1698.
17. Lewis, J.D., Goerlich, D., and Mattaj, I.W.. (1996)." A yeast cap binding protein complex (yCBC) acts at an early step in pre-mRNA splicing". *Nucleic Acids Res.*, **24**, 3332-3336.
18. Izaurralde, E., Lewis, J., Gamberi, C., Jarmolowski, A., mcGuigan, C., and Mattaj, I.W..(1995). "A cap-binding protein complex mediating U snRNA export". *Nature*, **376**: 709-712.
19. Gorlich, D., Kraft, R., Kostka, S., Vogel, F., Hartmann, E., Laskey, R.A., Mattaj, I.W., and Izaurralde, E.(1996). "Importin provides a link between nuclear protein import and U snRNA export". *Cell*, **87**:21-32.
20. Flaherty, S., Fortes, P., Izaurralde, E., Mattaj, I.W., and Gilmartin, G.M..(1997). " Participation of the nuclear cap binding complex in pre-mRNA 3' processing". *Proc.Natl. Acad.Sci.*, **94**:11893-11898.
21. Forte, P., Inada, T., Preiss, T., Hetze, M. and Sachs, A..(2000). "The Yeast Nuclear Cap Binding Complex can interact with translation factor eIF4G and mediate translation initiation". *Mol Cell*, **6**:191-196.
22. Ishigaki, Y. Li X. Serin G and Maquat L.E..”Evidence for a pioneer round of mRNA translation: mRNAs subject to nonsense mediated decay in mammalian cells are bound by CBP80 and CBP20” (2001). *Cell*, **106**:607-617.
23. Das B., Guo Z., Russo P., Chartland P and Sherman F.: The role of nuclear cap binding protein CBC1p of yeast in mRNA Termination and degradation. (2000). *Molec. Cell. Biol.*, **20** (8):2827-2838.
- 24.Mazza C., Ohno M., Segref A., Mattaj I.W. and Cusack S. “Crystal structure of the Human Nuclear Cap Binding Complex. (2001), **8**:383-396.
25. Avis J.M., Allain F.H.T., Howe P.W. Varani G., et al. “Solution structure of the N-terminal domain of UA1 protein: The role of C-terminal residues in structural stability and RNA binding (1996). *J. Mol. Biol.* **257**:398-411.
26. Varani G and Nagai K. “RNA recognition by RNP proteins during RNA processing (1998). *Ann. Rev. Biophys. Biomol. Struct.* 1998, **27**:407-45.
- 27 .Marcotrigiano J, Gringas A, Sonnenberg N and Burley S K.. (1997). “Cocrystal structure of the messenger RNA 5’ cap binding protein) eIF4E bound to 7-methyl GTP”. *Cell* , **85**: 951-961.
- 28 Hodel, A.E., Gershon, P.D., Quijcho, F.A..(1998). “Structural basis for sequence non-specific recognition of 5’-capped mRNA by a cap modifying enzyme”. *Mol. Cell.*, **1**:443-447.
- 29.Quijcho, F., Hu, G., Gershon, P..(2000). “ Structural basis of mRNA cap recognition by proteins”. *Current*

30 Mader, S., Lee, H., Pause, A. and Sonenberg, N..(1995). " The translation initiation factor eIF-4E binds to a common motif shared by the translation factor eIF4G and the translational repressors 4 E-binding proteins. *Mol. Cell. Biol.*, **15**:4990-4997.

31.Imatake, H., Gradi, A. and Sonenberg, N..)(1998). " A newly identified N-terminal amino acid sequence of human eIF4G binds poly(A)-binding protein and function in poly(A)-dependent translation". *EMBO J.*, **17**:7480-7489.

32. Ptushkina, M., Von der Haar, T., Vasilescu, S., Frank, R., Birkenhager, R. and McCarthy, J.E.G.(1998). " Cooperative modulation by eIF4G of eIF4E binding to the mRNA 5'cap in yeast involves a site partially shared by p20". *EMBO J.*, **17**, 4798-4808.